Where the Biotech Bets Are
Where the Biotech Bets Are
John McCamant of The Medical Technology Stock Letter tells where he’s making his in this poorly performing sector.
Biotech lobbyists' clout grows in Washington
Biotech lobbyists’ clout grows in Washington
The Biotechnology Industry Organization is still unpacking from its move into a bigger office a few blocks from the White House, underscoring the outfit’s rapid climb to lobbying juggernaut status.
Gene Doping Threatens to Transform Sports
Gene Doping Threatens to Transform Sports
“If it does take off, sport as we know it will disappear”
FDA Acts To Speed Bioterror Medicines
FDA Acts To Speed Bioterror Medicines
Responding to the threat of anthrax and other forms of chemical and biological terrorism, the Food and Drug Administration adopted new rules yesterday that will speed the approval of drugs that could protect people from attacks.
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
Recent Comments